Clinical Trial Update: Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing nivolumab versus everolimus in previously treated advanced or metastatic clear-cell renal cell carcinoma has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2016-04-29